Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD)
Source · ClinicalTrials.gov: elamipretide
TLDR
ClinicalTrials.gov lists SPIMD-301, a 48-week trial evaluating elamipretide in people with primary mitochondrial myopathy associated with nuclear DNA mutations, as completed. The randomized, double-blind, placebo-controlled study assessed efficacy and safety; the excerpt provides no results.
- 01SPIMD-301 is listed as completed.
- 02The 48-week study used a randomized, double-blind, parallel-group, placebo-controlled design.
- 03No efficacy findings or safety outcomes are reported in the excerpt.
Why it matters Editorial
The listing documents completion of an elamipretide trial but does not establish whether the treatment was effective or safe.
Summary generated with AI and reviewed by an editor. The original source governs; summaries can contain errors. Information only — not medical advice. Full disclaimer.
ClinicalTrials.gov: elamipretide
ClinicalTrials.gov: elamipretide
ClinicalTrials.gov: elamipretide
ClinicalTrials.gov: elamipretide